长期服用左旋多巴等多巴胺能药物治疗帕金森病(PD)可诱发运动并发症(MC)。目前认为MC与黑质致密部多巴胺能神经元的缺失程度以及多巴胺能药物对纹状体突触后膜相关受体的脉冲样刺激有关。近年来,有大量研究致力于开发多巴胺能药物的新剂型,探寻提高药物疗效与降低MC发生之间的平衡点。
Motor complications(MC) are the most common problem of chronic dopaminergic therapy in Parkinson's disease. It has been proposed that the nigrostriatal degeneration and nonphysiological pulsatile stimulation of striatal dopamine receptors play a key role in the development of MC. In recent years, numerous new formulations of dopaminergic drugs have been developed to explore the balance of Parkinson's disease treatment and MC.